Research and Clinical Trials

Brief Description  
HIV treatment experienced study looking at those on a current regimen containing EFV/FTC/TDF FDC (Atripla) to continue treatment, versus switching to FTC/RPV/TAF FDC.
Who may be Eligible  
Adults ages 18 years or older; currently receiving antiretroviral regimen containing EFV/FTC/TDF FDC (Atripla) for =6 consecutive months prior to screening; Plasma HIV-1 RNA levels <50 copies/mL for at least 6 months prior to screening visit and at screening visit; Normal ECG; Normal maintenance lab values; Not pregnant, nursing, or planning to become pregnant during trial or considering fathering a child while on treatment; Female subjects who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least 3 months prior to study dosing; Not Hepatitis C positive; No implanted defibrillator or pacemaker; No history of malignancy with past 5 years; No active serious infections other than HIV; No participation in other clinical trials; Not taking one of a list of disallowed medications; No documented resistance to any of study agents at any time in past; Serum amylase =5x ULN (subjects with serum amylast >5x ULN will remain eligible if Serum lipase is =5X ULN); Adequate renal function
Start Date  
IRB Number  
Principal Investigator  
Polk, Christopher
Contact Name  

For More Information, Contact   Lisa  A.  Engel
Phone:  (740) 667-5324  Fax:  (704) 331-9266 
Address:  4539 Hedgemore Drive, Suite 100
Charlotte, NC 28209